Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405353 · ClinicalTrials.gov registry record · Phase 1
Testosterone Treatment for Multiple Sclerosis
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00405353 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 10 participants.
The verdict
NCT00405353, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.
Interventions
- DRUG Androgel 10 grams of gel containing 100 mg of testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2002-04 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00405353
The ClinicalTrials.gov registry entry for NCT00405353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Androgel 10 grams of gel containing 100 mg of testosterone is the first listed.
NCT00405353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00405353 about?
NCT00405353 is a clinical study titled "Testosterone Treatment for Multiple Sclerosis". Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.
What is the current status of trial NCT00405353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2002-04. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00405353?
The interventions under investigation include: Androgel 10 grams of gel containing 100 mg of testosterone (DRUG).
Who is sponsoring clinical trial NCT00405353?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.